ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 995.3 | 1041.3 | 974.4 |
| Other income | 36.0 | 32.1 | 40.7 |
| Total income | 1031.2 | 1073.4 | 1015.0 |
| Profit before exceptional items & tax | 373.1 | 381.9 | 358.6 |
| Exceptional items | 0.0 | 18.0 | 0.0 |
| Profit before tax | 373.1 | 399.9 | 358.6 |
| Net profit | 277.9 | 295.6 | 262.9 |
| Operating margin | 36.2% | 37.3% | 35.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +5.70% |
|---|---|
| Net profit, quarter on quarter | -6.00% |
| Revenue, year on year | +2.10% |
BSE results filing, NSE: GLAXO. Figures extracted from the filing.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,701.40
- Market cap
- ₹45,763 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 39.9×Sector 43.8×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
Revenue ₹1,180 Cr, up 21% YoY, flattered by low base and GST tailwinds; underlying growth 12–13%. EBITDA margin held near 34% despite ~120 bps gross margin dilution. PAT boosted by a ₹42 Cr one-off.
GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue ₹1,180cr (+21%), EBITDA ₹400cr (34% margin), PAT ₹335cr (+33%). Innovation portfolio now 7% of sales, driving portfolio transformation.
GlaxoSmithKline Pharmaceuticals Management Change
GlaxoSmithKline Pharmaceuticals appointed Sandeep Seth as Head - Ethics & Compliance, effective 3 November 2026. He brings over 20 years of compliance and governance experience.
GlaxoSmithKline Pharmaceuticals Other Announcement
GSK Pharmaceuticals appointed M/s. Walker Chandiok & Co. LLP as Statutory Auditor, effective 1 April 2027 for a 60-month term. The appointment was approved at the board meeting held on 3 November 2026.
- Execution
- 1 April 2027 for 60 months
GlaxoSmithKline Pharmaceuticals Results Update
GSK Pharmaceuticals reported Q2 FY27 media release showing revenue of INR 1180 crore (up 21%) and PAT of INR 335 crore (up 31%). The release also announces the upcoming BLENREP launch in India.
GlaxoSmithKline Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.9 Cr, Up 30.4% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹1,184 Cr (+20.8% YoY) and net profit of ₹335.9 Cr (+30.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.9 Cr · +30.4% YoY